Microbot Medical Granted China Patent, Aims for Q3 2025 US Launch
ByAinvest
Wednesday, Jul 9, 2025 7:21 am ET1min read
MBOT--
The LIBERTY System, which is currently awaiting FDA 510(k) clearance, is expected to revolutionize endovascular robotics by eliminating traditional barriers to accessing advanced robotic systems. The system is designed to be fully disposable and single-use, making it a more accessible option for healthcare providers and patients alike.
Microbot Medical has announced plans to launch the LIBERTY System in the US during the third quarter of 2025. The company is currently strengthening its sales and marketing infrastructure in anticipation of the launch, while awaiting the anticipated FDA 510(k) decision during the current quarter.
The LIBERTY System's innovative design and potential market demand have been recognized by the Society of Robotic Surgery (SRS), which has invited Microbot Medical to participate in its inaugural Endovascular Robotics session at the SRS annual meeting in Strasbourg, France from July 16-20, 2025. The session, titled "Endovascular Robotics; the next frontier for robotic surgery," will feature a presentation by Microbot Medical's CEO, Harel Gadot, who will discuss the endovascular robotic market and the company's LIBERTY System [2].
Microbot Medical's patent portfolio and the upcoming launch of the LIBERTY System in the US indicate a strong commitment to innovation and market growth in the endovascular robotics space. As the company continues to develop and commercialize its products, investors and financial professionals should closely monitor Microbot Medical's progress and regulatory approvals.
References:
[1] https://www.stocktitan.net/news/MBOT/microbot-medical-to-open-inaugural-endovascular-robotics-session-at-238yddrsag8h.html
[2] https://www.marketscreener.com/quote/stock/MICROBOT-MEDICAL-INC-45615636/news/Microbot-Medical-to-Open-Inaugural-Endovascular-Robotics-Session-at-the-Society-of-Robotic-Surgery-50457413/
Microbot Medical has secured a patent in China for its LIBERTY System, a robotic endovascular system for minimally invasive procedures. The patent, granted by China's National Intellectual Property Administration, covers the robotic manipulation of a surgical tool handle. The company plans to launch the LIBERTY System in the US in Q3 2025. Microbot Medical's patent portfolio now includes 9 granted patents globally and 59 pending patent applications.
Microbot Medical Inc. (NASDAQ: MBOT), a leading medical technology company, has received a patent in China for its LIBERTY System, a robotic endovascular system designed for minimally invasive procedures. The patent, granted by China's National Intellectual Property Administration, covers the robotic manipulation of a surgical tool handle. This latest patent addition brings Microbot Medical's global patent portfolio to 9 granted patents and 59 pending applications [1].The LIBERTY System, which is currently awaiting FDA 510(k) clearance, is expected to revolutionize endovascular robotics by eliminating traditional barriers to accessing advanced robotic systems. The system is designed to be fully disposable and single-use, making it a more accessible option for healthcare providers and patients alike.
Microbot Medical has announced plans to launch the LIBERTY System in the US during the third quarter of 2025. The company is currently strengthening its sales and marketing infrastructure in anticipation of the launch, while awaiting the anticipated FDA 510(k) decision during the current quarter.
The LIBERTY System's innovative design and potential market demand have been recognized by the Society of Robotic Surgery (SRS), which has invited Microbot Medical to participate in its inaugural Endovascular Robotics session at the SRS annual meeting in Strasbourg, France from July 16-20, 2025. The session, titled "Endovascular Robotics; the next frontier for robotic surgery," will feature a presentation by Microbot Medical's CEO, Harel Gadot, who will discuss the endovascular robotic market and the company's LIBERTY System [2].
Microbot Medical's patent portfolio and the upcoming launch of the LIBERTY System in the US indicate a strong commitment to innovation and market growth in the endovascular robotics space. As the company continues to develop and commercialize its products, investors and financial professionals should closely monitor Microbot Medical's progress and regulatory approvals.
References:
[1] https://www.stocktitan.net/news/MBOT/microbot-medical-to-open-inaugural-endovascular-robotics-session-at-238yddrsag8h.html
[2] https://www.marketscreener.com/quote/stock/MICROBOT-MEDICAL-INC-45615636/news/Microbot-Medical-to-Open-Inaugural-Endovascular-Robotics-Session-at-the-Society-of-Robotic-Surgery-50457413/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet